T. Rowe Price Associates’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-119,288
| Closed | -$2.56M | – | 3262 |
|
|
2026
Q1 | $2.56M | Buy |
119,288
+16,832
| +16% | +$237K | ﹤0.01% | 1723 |
|
|
2025
Q4 | $955K | Buy |
102,456
+22,723
| +28% | +$190K | ﹤0.01% | 2103 |
|
|
2025
Q3 | $563K | Sell |
79,733
-1,040,898
| -93% | -$7.16M | ﹤0.01% | 2314 |
|
|
2025
Q2 | $7.29M | Sell |
1,120,631
-52,463
| -4% | -$361K | ﹤0.01% | 1190 |
|
|
2025
Q1 | $9.3M | Sell |
1,173,094
-533,018
| -31% | -$5.74M | ﹤0.01% | 1126 |
|
|
2024
Q4 | $21.6M | Sell |
1,706,112
-838,751
| -33% | -$11.7M | ﹤0.01% | 980 |
|
|
2024
Q3 | $35.5M | Buy |
2,544,863
+193,983
| +8% | +$2.77M | ﹤0.01% | 848 |
|
|
2024
Q2 | $32.4M | Buy |
2,350,880
+51,116
| +2% | +$748K | ﹤0.01% | 839 |
|
|
2024
Q1 | $38M | Sell |
2,299,764
-17,000
| -0.7% | -$254K | ﹤0.01% | 792 |
|
|
2023
Q4 | $33.8M | Buy |
2,316,764
+8,736
| +0.4% | +$106K | ﹤0.01% | 808 |
|
|
2023
Q3 | $28.3M | Sell |
2,308,028
-1,703
| -0.1% | -$22.2K | ﹤0.01% | 833 |
|
|
2023
Q2 | $27.6M | Buy |
2,309,731
+644,980
| +39% | +$8.42M | ﹤0.01% | 850 |
|
|
2023
Q1 | $22.3M | Sell |
1,664,751
-517,827
| -24% | -$10.1M | ﹤0.01% | 895 |
|
|
2022
Q4 | $47M | Buy |
2,182,578
+87,665
| +4% | +$1.8M | 0.01% | 677 |
|
|
2022
Q3 | $42M | Buy |
2,094,913
+53,569
| +3% | +$1.14M | 0.01% | 699 |
|
|
2022
Q2 | $36.5M | Buy |
2,041,344
+455,603
| +29% | +$4.7M | ﹤0.01% | 984 |
|
|
2022
Q1 | $15.7M | Buy |
1,585,741
+4,763
| +0.3% | +$62.9K | ﹤0.01% | 1293 |
|
|
2021
Q4 | $26.6M | Buy |
1,580,978
+74,652
| +5% | +$1.53M | ﹤0.01% | 1208 |
|
|
2021
Q3 | $34.9M | Buy |
1,506,326
+930
| +0.1% | +$22.3K | ﹤0.01% | 1136 |
|
|
2021
Q2 | $33.4M | Buy |
+1,505,396
| New | +$31.4M | ﹤0.01% | 1168 |
|
Other funds holding DAWN
T. Rowe Price Associates's DAWN Position: Q2 2026 in Review
T. Rowe Price Associates sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 119,288 shares — an estimated $2.56M sold.
T. Rowe Price Associates first reported a position in DAWN in Q2 2021 and held it in 20 quarters. The position peaked at $47M in Q4 2022. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- T. Rowe Price Associates reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- T. Rowe Price Associates sold 119,288 Day One Biopharmaceuticals shares in Q2 2026, an estimated $2.56M.
- T. Rowe Price Associates first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 20 quarters.
- T. Rowe Price Associates's Day One Biopharmaceuticals position peaked at $47M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.